Division of Cardiology, Lehigh Valley Health Network, 1200 S. Cedar Crest Blvd, Allentown, PA, 18103, USA.
Maulana Azad Medical College, Delhi, 110092, India.
Heart Fail Rev. 2019 Mar;24(2):189-197. doi: 10.1007/s10741-018-9752-6.
Hypertrophic cardiomyopathy (HCM) is the most common hereditary cardiomyopathy characterized by left ventricular hypertrophy and spectrum of clinical manifestation. Atrial fibrillation (AF) is a common sustained arrhythmia in HCM patients and is primarily related to left atrial dilatation and remodeling. There are several clinical, electrocardiographic (ECG), and echocardiographic (ECHO) features that have been associated with development of AF in HCM patients; strongest predictors are left atrial size, age, and heart failure class. AF can lead to progressive functional decline, worsening heart failure and increased risk for systemic thromboembolism. The management of AF in HCM patient focuses on symptom alleviation (managed with rate and/or rhythm control methods) and prevention of complications such as thromboembolism (prevented with anticoagulation). Finally, recent evidence suggests that early rhythm control strategy may result in more favorable short- and long-term outcomes.
肥厚型心肌病(HCM)是最常见的遗传性心肌病,其特征为左心室肥厚和临床表现谱。心房颤动(AF)是 HCM 患者常见的持续性心律失常,主要与左心房扩张和重构有关。有一些临床、心电图(ECG)和超声心动图(ECHO)特征与 HCM 患者发生 AF 相关;最强的预测因子是左心房大小、年龄和心力衰竭分级。AF 可导致进行性功能下降、心力衰竭恶化和全身性血栓栓塞风险增加。HCM 患者的 AF 管理侧重于症状缓解(通过控制心率和/或节律的方法进行管理)和预防并发症(如血栓栓塞)(通过抗凝预防)。最后,最近的证据表明,早期节律控制策略可能会带来更有利的短期和长期结果。